Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases
Agency: National Institutes of Health
- 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
Forecasted opportunityLast Updated: Jun 10, 2026
Important dates
- Forecasted post date: September 1, 2026
- Forecasted application due date: March 4, 2027
- Forecasted award date: March 4, 2027
- Forecasted project start date: March 4, 2027
- Fiscal Year: 2027
Award details
- Expected project funding: Not specified
- Expected awards: 4
Award min.
$300,000
Award max.
$600,000
- Funding opportunity number:PAR-27-109
- Cost sharing or matching requirement:No
- Funding instrument type:
- Grant
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Health
- Category Explanation:Not specified
History
- Forecast posted date: June 10, 2026
- Archive date: Not specified
- Version: 1
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Exploratory Clinical Trials Grants Program in the mission areas of NIAMS. The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases.
Examples of research areas of interest include, but are not limited to:
- Conducting early-stage clinical trials, such as but not limited to; first in human, dose-finding or escalation/tolerability/safety/efficacy studies with drugs, biologics, devices, behavioral interventions, and/or physical therapy for treatment of arthritis, musculoskeletal, or skin conditions or diseases.
- Clinical trials to provide data required to support a future, more robust clinical trial whose aim is to help establish the safety and efficacy or effectiveness of an intervention.
- Clinical trials in rare diseases where the number of potential study participants is limited.
- Clinical trials to determine the predictive value of a potential biomarker.
Eligibility
Business
- For-profit organizations other than small businesses
- Small businesses
Government
- City or township governments
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- Special district governments
- State governments
- County governments
Education
- Private institutions of higher education
- Public and state institutions of higher education
- Independent school districts
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
Miscellaneous
- Other
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: NIAMS_NOFOs@mail.nih.gov
NIAMS_NOFOs@mail.nih.gov
Link to additional information
No additional information is available
HHS.gov
An official website of the U.S. Department of Health and Human Services
